Planned interim analysis of a phase II trial of concurrent durvalumab and radiation therapy for locally advanced lung cancer Meeting Abstract
| Authors: | Rimner, A.; Fitzgerald, K.; Iqbal, A. N.; Shepherd, A. F.; Gomez, D. R.; Shin, J. Y.; Gelblum, D. Y.; Hajj, C.; Albrecht, F.; Kotecha, R. R.; Preeshagul, I. R.; Santini, F. C.; Shaverdian, N.; Wu, A. J.; Simone, C. B. 2nd; Ginsberg, M. S.; Zhang, Z.; Offin, M. D.; Kris, M. G.; Chaft, J. E. |
| Abstract Title: | Planned interim analysis of a phase II trial of concurrent durvalumab and radiation therapy for locally advanced lung cancer |
| Meeting Title: | 2022 World Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 17 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2022 Aug 6-9 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-09-01 |
| Start Page: | S278 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2022.07.472 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: EP05.01-025 -- Located within section named "EP05.01 Locally Advanced Non-Small Cell Lung Cancer - Chemoradiotherapy And Radiotherapy" -- Accession Number: 159037718 -- Entry Date: In Process -- Revision Date: 20220913 -- Publication Type: Article -- Supplement Title: 2022 Supplement -- Journal Subset: Biomedical; Blind Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101274235. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
